Arvest Bank Trust Division Buys 64,269 Shares of CVS Health Corporation $CVS

Arvest Bank Trust Division increased its stake in shares of CVS Health Corporation (NYSE:CVS) by 2,401.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 66,945 shares of the pharmacy operator’s stock after acquiring an additional 64,269 shares during the period. Arvest Bank Trust Division’s holdings in CVS Health were worth $4,808,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of CVS Health in the fourth quarter valued at approximately $1,666,265,000. Wellington Management Group LLP boosted its holdings in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after buying an additional 12,233,675 shares during the period. Amundi grew its stake in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Vanguard Group Inc. raised its holdings in CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares during the period. Finally, Davis Selected Advisers lifted its position in CVS Health by 11.9% during the 4th quarter. Davis Selected Advisers now owns 12,760,511 shares of the pharmacy operator’s stock worth $1,012,675,000 after acquiring an additional 1,356,870 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.

CVS Health Stock Up 2.6%

Shares of NYSE:CVS opened at $110.40 on Wednesday. The company has a market capitalization of $140.87 billion, a PE ratio of 48.64, a P/E/G ratio of 1.05 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The company’s fifty day moving average is $99.58 and its 200-day moving average is $85.58. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $110.62.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced that common prescription medications for dogs and cats are now available at its roughly 9,000 CVS Pharmacy locations nationwide, expanding the chain’s role beyond human prescriptions and potentially adding a small but incremental revenue stream while increasing store traffic. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Market commentary highlighted that CVS has been outperforming the broader market, reflecting continued investor confidence in the company’s ongoing operational improvement and turnaround efforts. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Positive Sentiment: Another report echoed the same outperformance theme, noting CVS’s strong trading versus the market and suggesting that investors remain focused on the company’s improving fundamentals. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: A longer-form analysis argued CVS is still in the middle of a meaningful turnaround, with improving margins, declining leverage, and strong cash flow, but it also noted the stock is no longer viewed as a deep bargain after its rally. CVS Health Update: The C- Student Now Pulling Down A B+

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. UBS Group increased their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Argus lifted their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Finally, DA Davidson raised their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.